Peroxisome proliferator-activated receptor-α and liver cancer: where do we stand? (original) (raw)
Hess R, Staubli W, Reiss W (1965) Nature of the hepatomegalic effect produced by ethyl-chlorphenoxyisobutyrate in the rat. Nature 208:856–858 Google Scholar
Reddy JK, Krishnakantha TP (1975) Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate. Science 190:787–789 CASPubMed Google Scholar
Reddy JK, Azarnoff DL, Hignite CE (1980) Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283:397–398 Google Scholar
Reddy JK, Lalwai ND (1983) Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit Rev Toxicol 12:1–58 CASPubMed Google Scholar
Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645–650 Google Scholar
Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68:879–887 ArticleCASPubMed Google Scholar
Kliewer SA, Forman BM, Blumberg B et al (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 91:7355–7359 CASPubMed Google Scholar
Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649–688 ArticleCASPubMed Google Scholar
Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94:4312–4317 ArticleCASPubMed Google Scholar
Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W (1993) Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor–retinoid X receptor heterodimers. Proc Natl Acad Sci U S A 90:2160–2164 CASPubMed Google Scholar
Kliewer SA, Sundseth SS, Jones SA et al (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 94:4318–4323 ArticleCASPubMed Google Scholar
Krey G, Braissant O, L’Horset F et al (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11:779–791 ArticleCASPubMed Google Scholar
Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK (1998) Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 273:15639–15645 Google Scholar
Shearer BG, Hoekstra WJ (2003) Recent advances in peroxisome proliferator-activated receptor science. Curr Med Chem 10:267–280 CASPubMed Google Scholar
Sumanasekera WK, Tien ES, Davis JW II, Turpey R, Perdew GH, Vanden Heuvel JP (2003) Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta activity. Biochemistry 42:10726–10735 ArticleCASPubMed Google Scholar
Sumanasekera WK, Tien ES, Turpey R, Vanden Heuvel JP, Perdew GH (2003) Evidence that peroxisome proliferator-activated receptor alpha is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2. J Biol Chem 278:4467–4473 Google Scholar
Glass CK, Rosenfeld MG (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121–141 CASPubMed Google Scholar
Puigserver P, Adelmant G, Wu Z et al (1999) Activation of PPARgamma coactivator-1 through transcription factor docking. Science 286:1368–1371 ArticleCASPubMed Google Scholar
Jia Y, Qi C, Kashireddi P et al (2004) Transcription coactivator PBP, the peroxisome proliferator-activated receptor (PPAR)-binding protein, is required for PPARalpha-regulated gene expression in liver. J Biol Chem 279:24427–24434 Google Scholar
Mandard S, Muller M, Kersten S (2004) Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61:393–416 ArticleCASPubMed Google Scholar
Cherkaoui-Malki M, Meyer K, Cao WQ et al (2001) Identification of novel peroxisome proliferator-activated receptor alpha (PPARalpha) target genes in mouse liver using cDNA microarray analysis. Gene Expr 9:291–304 Google Scholar
Chu R, Lim H, Brumfield L et al (2004) Protein profiling of mouse livers with peroxisome proliferator-activated receptor alpha activation. Mol Cell Biol 24:6288–6297 ArticleCASPubMed Google Scholar
Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137:354–366 ArticleCASPubMed Google Scholar
Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B (2001) Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142:4195–4202 ArticleCASPubMed Google Scholar
Yeldandi AV, Rao MS, Reddy JK (2000) Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. Mutat Res 448:159–177 CASPubMed Google Scholar
Peters JM, Cattley RC, Gonzalez FJ (1997) Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18:2029–2033 ArticleCASPubMed Google Scholar
Hays T, Rusyn I, Burns AM et al (2005) Role of peroxisome proliferator-activated receptor-{alpha} (PPAR{alpha}) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26:219–227 ArticleCASPubMed Google Scholar
Klaunig JE, Babich MA, Baetcke KP et al (2003) PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol 33:655–780 CASPubMed Google Scholar
Moya-Camarena SY, Vanden Heuvel JP, Blanchard SG, Leesnitzer LA, Belury MA (1999) Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARalpha. J Lipid Res 40:1426–1433 CASPubMed Google Scholar
Mukherjee R, Sun S, Santomenna L et al (2002) Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor alpha. J Steroid Biochem Mol Biol 81:217–225 ArticleCASPubMed Google Scholar
Gould SJ, Keller GA, Subramani S (1988) Identification of peroxisomal targeting signals located at the carboxy terminus of four peroxisomal proteins. J Cell Biol 107:897–905 ArticleCASPubMed Google Scholar
Gould SJ, Keller GA, Hosken N, Wilkinson J, Subramani S (1989) A conserved tripeptide sorts proteins to peroxisomes. J Cell Biol 108:1657–1664 ArticleCASPubMed Google Scholar
Marsman DS, Cattley RC, Conway JG, Popp JA (1988) Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer Res 48:6739–6744 CASPubMed Google Scholar
Nemali MR, Reddy MK, Usuda N et al (1989) Differential induction and regulation of peroxisomal enzymes: predictive value of peroxisome proliferation in identifying certain nonmutagenic carcinogens. Toxicol Appl Pharmacol 97:72–87 ArticleCASPubMed Google Scholar
Reddy JK, Lalwani ND, Reddy MK, Qureshi SA (1982) Excessive accumulation of autofluorescent lipofuscin in the liver during hepatocarcinogenesis by methyl clofenapate and other hypolipidemic peroxisome proliferators. Cancer Res 42:259–266 CASPubMed Google Scholar
Marsman DS, Goldsworthy TL, Popp JA (1992) Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid. Carcinogenesis 13:1011–1017 CASPubMed Google Scholar
Ikeda H, Tauchi H, Shimasaki H, Ueta N, Sato T (1985) Age and organ difference in amount and distribution of autofluorescent granules in rats. Mech Ageing Dev 31:139–146 CASPubMed Google Scholar
Glauert HP, Beaty MM, Clark TD, Greenwell WS, Chow CK (1990) Effect of dietary selenium on the induction of altered hepatic foci and hepatic tumors by the peroxisome proliferator ciprofibrate. Nutr Cancer 14:261–271 CASPubMed Google Scholar
Rao MS, Lalwani ND, Watanabe TK, Reddy JK (1984) Inhibitory effect of antioxidants ethoxyquin and 2(3)-_tert_-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator. Cancer Res 44:1072–1076 CASPubMed Google Scholar
Glauert HP, Srinivasan S, Tatum VL et al (1992) Effects of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cellular antioxidants and lipid peroxidation in rats. Biochem Pharmacol 43:1353–1359 ArticleCASPubMed Google Scholar
O’Brien ML, Twaroski TP, Cunningham ML, Glauert HP, Spear BT (2001) Effects of peroxisome proliferators on antioxidant enzymes and antioxidant vitamins in rats and hamsters. Toxicol Sci 60:271–278 ArticleCASPubMed Google Scholar
Cattley RC, DeLuca J, Elcombe C et al (1998) Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol 27:47–60 ArticleCAS Google Scholar
Rusyn I, Asakura S, Pachkowski B et al (2004) Expression of base excision DNA repair genes is a sensitive biomarker for in vivo detection of chemical-induced chronic oxidative stress: identification of the molecular source of radicals responsible for DNA damage by peroxisome proliferators. Cancer Res 64:1050–1057 CASPubMed Google Scholar
Fan CY, Pan J, Chu R et al (1996) Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. J Biol Chem 271:24698–24710 Google Scholar
O’Brien ML, Spear BT, Glauert HP (2005) Role of oxidative stress in peroxisome proliferator-mediated carcinogenesis. Crit Rev Toxicol 35:61–88 ArticleCAS Google Scholar
Rose ML, Rusyn I, Bojes HK, Belyea J, Cattley RC, Thurman RG (2000) Role of Kupffer cells and oxidants in signaling peroxisome proliferator-induced hepatocyte proliferation. Mutat Res 448:179–192 CASPubMed Google Scholar
Peters JM, Aoyama T, Cattley RC, Nobumitsu U, Hashimoto T, Gonzalez FJ (1998) Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver. Carcinogenesis 19:1989–1994 ArticleCASPubMed Google Scholar
Anderson SP, Dunn CS, Cattley RC, Corton JC (2001) Hepatocellular proliferation in response to a peroxisome proliferator does not require TNFalpha signaling. Carcinogenesis 22:1843–1851 ArticleCASPubMed Google Scholar
Lawrence JW, Wollenberg GK, DeLuca JG (2001) Tumor necrosis factor alpha is not required for WY14,643-induced cell proliferation. Carcinogenesis 22:381–386 ArticleCASPubMed Google Scholar
Roberts RA, James NH, Hasmall SC et al (2000) Apoptosis and proliferation in nongenotoxic carcinogenesis: species differences and role of PPARalpha. Toxicol Lett 112–113:49–57 Google Scholar
Fruchart JC, Brewer HB Jr, Leitersdorf E (1998) Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 81:912–917. Review ArticleCASPubMed Google Scholar
Bility M, Thompson JT, McKee RH et al (2004) Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. Toxicol Sci 82:170–182 Google Scholar
Hasmall SC, James NH, Macdonald N, Soames AR, Roberts RA (2000) Species differences in response to diethylhexylphthalate: suppression of apoptosis, induction of DNA synthesis and peroxisome proliferator activated receptor alpha-mediated gene expression. Arch Toxicol 74:85–91 ArticleCASPubMed Google Scholar
Lawrence JW, Li Y, Chen S et al (2001) Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPARalpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J Biol Chem 276:31521–31527 Google Scholar
Maloney EK, Waxman DJ (1999) Trans-activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals. Toxicol Appl Pharmacol 161:209–218 ArticleCASPubMed Google Scholar
Sher T, Yi HF, McBride OW, Gonzalez FJ (1993) cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32:5598–5604 Google Scholar
Anthony LE, Schmucker DL, Mooney JS, Jones AL (1978) A quantitative analysis of fine structure and drug metabolism in livers of clofibrate-treated young adult and retired breeder rats. J Lipid Res 19:154–165 CASPubMed Google Scholar
Hanefeld M, Kemmer C, Kadner E (1983) Relationship between morphological changes and lipid-lowering action of _p_-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis 46:239–246 CASPubMed Google Scholar
Hanefeld M, Kemmer C, Leonhardt W, Kunze KD, Jaross W, Haller H (1980) Effects of _p_-chlorophenoxyisobutyric acid (CPIB) on the human liver. Atherosclerosis 36:159–172 CASPubMed Google Scholar
De La Iglesia FA, Lewis JE, Buchanan RA, Marcus EL, McMahon G (1982) Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis 43:19–37 PubMed Google Scholar
Blumcke S, Schwartzkopff W, Lobeck H, Edmondson NA, Prentice DE, Blane GF (1983) Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis 46:105–116 CASPubMed Google Scholar
Gariot P, Barrat E, Drouin P et al (1987) Morphometric study of human hepatic cell modifications induced by fenofibrate. Metabolism 36:203–210 ArticleCASPubMed Google Scholar
Doull J, Cattley R, Elcombe C et al (1999) A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines. Regul Toxicol Pharmacol 29:327–357 ArticleCASPubMed Google Scholar
Watanabe T, Horie S, Yamada J et al (1989) Species differences in the effects of bezafibrate, a hypolipidemic agent, on hepatic peroxisome-associated enzymes. Biochem Pharmacol 38:367–371 ArticleCASPubMed Google Scholar
Makowska JM, Gibson GG, Bonner FW (1992) Species differences in ciprofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation. J Biochem Toxicol 7:183–191 Google Scholar
Lake BG, Evans JG, Gray TJ, Korosi SA, North CJ (1989) Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset. Toxicol Appl Pharmacol 99:148–160 Google Scholar
Graham MJ, Wilson SA, Winham MA et al (1994) Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for 3 years. Fundam Appl Toxicol 22:58–64 ArticleCASPubMed Google Scholar
Lalwani ND, Reddy MK, Ghosh S, Barnard SD, Molello JA, Reddy JK (1985) Induction of fatty acid beta-oxidation and peroxisome proliferation in the liver of rhesus monkeys by DL-040, a new hypolipidemic agent. Biochem Pharmacol 34:3473–3482 ArticleCASPubMed Google Scholar
Reddy JK, Lalwani ND, Qureshi SA, Reddy MK, Moehle CM (1984) Induction of hepatic peroxisome proliferation in nonrodent species, including primates. Am J Pathol 114:171–183 CASPubMed Google Scholar
Hoivik DJ, Qualls CW Jr, Mirabile RC et al (2004) Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis 25:1757–1769 ArticleCASPubMed Google Scholar
Reddy JK, Goel SK, Nemali MR et al (1986) Transcriptional regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proc Natl Acad Sci U S A 83:1747–1751 CASPubMed Google Scholar
Roglans N, Bellido A, Rodriguez C et al (2002) Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. Clin Pharmacol Ther 72:692–701 Google Scholar
Reddy JK, Rao MS, Azarnoff DL, Sell S (1979) Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. Cancer Res 39:152–161 CASPubMed Google Scholar
Moody DE, Rao MS, Reddy JK (1977) Mitogenic effect in mouse liver induced by a hypolipidemic drug, nafenopin. Virchows Arch B Cell Pathol 23:291–296 CASPubMed Google Scholar
Parzefall W, Berger W, Kainzbauer E, Teufelhofer O, Schulte-Hermann R, Thurman RG (2001) Peroxisome proliferators do not increase DNA synthesis in purified rat hepatocytes. Carcinogenesis 22:519–523 ArticleCASPubMed Google Scholar
Karam WG, Ghanayem BI (1997) Induction of replicative DNA synthesis and PPAR alpha-dependent gene transcription by Wy-14 643 in primary rat hepatocyte and non-parenchymal cell co-cultures. Carcinogenesis 18:2077–2083 ArticleCASPubMed Google Scholar
Hall M, Matthews A, Webley L, Harling R (1999) Effects of di-isononyl phthalate (DINP) on peroxisomal markers in the marmoset-DINP is not a peroxisome proliferator. J Toxicol Sci 24:237–244 Google Scholar
Huttunen JK, Heinonen OP, Manninen V et al (1994) The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med 235:31–39 CASPubMed Google Scholar
Frick MH, Elo O, Haapa K et al (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237–1245 CASPubMed Google Scholar
Investigators CoP (1978) A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 40:1069–1118 Google Scholar
Investigators CoP (1980) W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 2:379–385 Google Scholar
Investigators CoP (1984) WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 2:600–604 Google Scholar
Sapone A, Peters JM, Sakai S et al (2000) The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 10:321–333 ArticleCASPubMed Google Scholar
Flavell DM, Pineda Torra I, Jamshidi Y et al (2000) Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia 43:673–680 ArticleCASPubMed Google Scholar
Vohl MC, Lepage P, Gaudet D et al (2000) Molecular scanning of the human PPARa gene. Association of the L162V mutation with hyperapobetalipoproteinemia. J Lipid Res 41:945–952 CASPubMed Google Scholar
Brisson D, Ledoux K, Bosse Y et al (2002) Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics 12:313–320 ArticleCASPubMed Google Scholar
Bosse Y, Pascot A, Dumont M et al (2002) Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. Genet Med 4:311–315 CASPubMed Google Scholar
Flavell DM, Jamshidi Y, Hawe E et al (2002) Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 105:1440–1445 ArticleCASPubMed Google Scholar
Robitaille J, Brouillette C, Houde A et al (2004) Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 49:482–489 ArticleCASPubMed Google Scholar
Puckey LH, Knight BL (2001) Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjects. Pharmacogenetics 11:619–624 ArticleCASPubMed Google Scholar
Yamakawa-Kobayashi K, Ishiguro H, Arinami T, Miyazaki R, Hamaguchi H (2002) A Val227Ala polymorphism in the peroxisome proliferator activated receptor alpha (PPARalpha) gene is associated with variations in serum lipid levels. J Med Genet 39:189–191 ArticleCASPubMed Google Scholar
Gervois P, Torra IP, Chinetti G et al (1999) A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. Mol Endocrinol 13:1535–1549 ArticleCASPubMed Google Scholar
Leung KC (2004) Regulation of cytokine receptor signaling by nuclear hormone receptors: a new paradigm for receptor interaction. DNA Cell Biol 23:463–474 ArticleCASPubMed Google Scholar
Waxman DJ (1999) P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 369:11–23 ArticleCASPubMed Google Scholar
Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF (1998) Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol 53:14–22 CASPubMed Google Scholar
Tugwood JD, Aldridge TC, Lambe KG, Macdonald N, Woodyatt NJ (1996) Peroxisome proliferator-activated receptors: structures and function. Ann N Y Acad Sci 804:252–265 Google Scholar
Walgren JE, Kurtz DT, McMillan JM (2000) Expression of PPAR(alpha) in human hepatocytes and activation by trichloroacetate and dichloroacetate. Res Commun Mol Pathol Pharmacol 108:116–132 CASPubMed Google Scholar
Cheung C, Akiyama TE, Ward JM et al (2004) Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor-α. Cancer Res 64:3849–3854 CASPubMed Google Scholar
Smith CL, O’Malley BW (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45–71 ArticleCASPubMed Google Scholar
Varanasi U, Chu R, Huang Q, Castellon R, Yeldandi AV, Reddy JK (1998) Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem 273:30842 Google Scholar
Varanasi U, Chu R, Huang Q, Castellon R, Yeldandi AV, Reddy JK (1996) Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem 271:2147–2155 Google Scholar
Woodyatt NJ, Lambe KG, Myers KA, Tugwood JD, Roberts RA (1999) The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. Carcinogenesis 20:369–372 ArticleCASPubMed Google Scholar
Lambe KG, Woodyatt NJ, Macdonald N, Chevalier S, Roberts RA (1999) Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol Lett 110:119–127 Google Scholar
Peters JM, Rusyn I, Rose ML, Gonzalez FJ, Thurman RG (2000) Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis 21:823–826 ArticleCASPubMed Google Scholar